ECSP17016797A - Indazoles sustituidos con benzilo como inhibidores de bub1 - Google Patents

Indazoles sustituidos con benzilo como inhibidores de bub1

Info

Publication number
ECSP17016797A
ECSP17016797A ECIEPI201716797A ECPI201716797A ECSP17016797A EC SP17016797 A ECSP17016797 A EC SP17016797A EC IEPI201716797 A ECIEPI201716797 A EC IEPI201716797A EC PI201716797 A ECPI201716797 A EC PI201716797A EC SP17016797 A ECSP17016797 A EC SP17016797A
Authority
EC
Ecuador
Prior art keywords
benzyl
indazoles substituted
bub1 inhibitors
bub1
inhibitors
Prior art date
Application number
ECIEPI201716797A
Other languages
English (en)
Inventor
Joachim Kuhnke
Simon Holton
Ursula Mönning
Marion Hitchcock
Lars Bärfacker
Hans Briem
Anne Mengel
Thomas Müller
Manfred Möwes
Arwed Cleve
Jens SCHRÖDER
Hans-Georg Lerchen
Amaury Ernesto Fernandez-Montalvan
Gerhard Siemeister
Wilhelm Bone
Original Assignee
Poli Nutri Alimentos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poli Nutri Alimentos S A filed Critical Poli Nutri Alimentos S A
Publication of ECSP17016797A publication Critical patent/ECSP17016797A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Compuestos de fórmula (I), como se definen en la presente y su uso como agentes farmacéuticos.
ECIEPI201716797A 2014-09-19 2017-03-17 Indazoles sustituidos con benzilo como inhibidores de bub1 ECSP17016797A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14185604 2014-09-19
EP15176903 2015-07-15

Publications (1)

Publication Number Publication Date
ECSP17016797A true ECSP17016797A (es) 2017-05-31

Family

ID=54140475

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201716797A ECSP17016797A (es) 2014-09-19 2017-03-17 Indazoles sustituidos con benzilo como inhibidores de bub1

Country Status (27)

Country Link
US (1) US10350206B2 (es)
EP (1) EP3194379A1 (es)
JP (1) JP6664385B2 (es)
KR (1) KR20170049604A (es)
CN (1) CN107001331A (es)
AP (1) AP2017009803A0 (es)
AU (1) AU2015316796A1 (es)
BR (1) BR112017005444A2 (es)
CA (1) CA2961589A1 (es)
CL (1) CL2017000654A1 (es)
CO (1) CO2017002532A2 (es)
CR (1) CR20170100A (es)
CU (1) CU20170029A7 (es)
DO (1) DOP2017000078A (es)
EA (1) EA032401B1 (es)
EC (1) ECSP17016797A (es)
IL (1) IL251071A0 (es)
MA (1) MA39484A (es)
MX (1) MX2017003664A (es)
NI (1) NI201700034A (es)
PE (1) PE20170697A1 (es)
PH (1) PH12017500509A1 (es)
SG (1) SG11201702082VA (es)
TN (1) TN2017000092A1 (es)
TW (1) TW201615636A (es)
UY (1) UY36311A (es)
WO (1) WO2016042084A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
LT3176170T (lt) 2012-06-13 2019-04-25 Incyte Holdings Corporation Pakeisti tricikliniai junginiai, kaip fgfr inhibitoriai
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
JP2016536311A (ja) 2013-10-30 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換ピラゾール類
CN106458986B (zh) 2014-02-06 2019-01-04 赫普泰雅治疗有限公司 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018188590A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210920A1 (es) 2018-05-04 2021-05-19 Incyte Corp Formas solidas de un inhibidor de fgfr y procesos para prepararlas
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
EP0934311B1 (de) 1996-10-14 2009-05-13 Bayer HealthCare AG Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
WO2004024159A1 (en) 2002-09-10 2004-03-25 Scios Inc. INHIBITORS OF TFGβ
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
CN101765596B (zh) 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US8354399B2 (en) 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
SI3415515T1 (sl) 2009-11-27 2020-03-31 Adverio Pharma Gmbh Postopek priprave metil-(4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo(3,4-b)piridin-3- il)pirimidin-5-il)metilkarbamata
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンジルピラゾール類
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
US20150141372A1 (en) 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
US20160052912A1 (en) 2013-03-21 2016-02-25 Bayer Pharma Akitiengesellschaft Diaminoheteroaryl substituted indazoles
US20160046604A1 (en) 2013-03-21 2016-02-18 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
CA2916097A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
EP3010901B1 (en) 2013-06-21 2017-09-13 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
US20160168130A1 (en) 2013-06-21 2016-06-16 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202586A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
JP2016536311A (ja) 2013-10-30 2016-11-24 バイエル ファーマ アクチエンゲゼルシャフト ヘテロアリール置換ピラゾール類
US20170305882A1 (en) 2014-09-19 2017-10-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
JP2017529353A (ja) 2014-09-19 2017-10-05 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
CN107148420A (zh) 2014-09-19 2017-09-08 拜耳制药股份公司 苄基取代的吲唑类化合物
BR112017003548A2 (pt) 2014-09-19 2017-12-12 Nestec Sa tratamento de câncer com inibidor de alfa-amilase para animais de estimação
EA033697B1 (ru) 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
ME03776B (me) 2014-09-19 2021-04-20 Forma Therapeutics Inc Derivati piridin-2(1h)-on hinolinona kao inhibitori mutirane izocitrat dehidrogenaze
WO2016042084A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 inhibitors
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
CR20170100A (es) 2017-04-24
CU20170029A7 (es) 2017-08-08
AP2017009803A0 (en) 2017-03-31
MA39484A (fr) 2016-03-24
EA032401B1 (ru) 2019-05-31
EP3194379A1 (en) 2017-07-26
SG11201702082VA (en) 2017-04-27
NI201700034A (es) 2017-06-16
JP2017530962A (ja) 2017-10-19
TN2017000092A1 (en) 2018-07-04
CA2961589A1 (en) 2016-03-24
CO2017002532A2 (es) 2017-07-11
UY36311A (es) 2016-04-29
DOP2017000078A (es) 2017-06-30
AU2015316796A1 (en) 2017-03-30
WO2016042084A1 (en) 2016-03-24
PH12017500509A1 (en) 2017-08-30
JP6664385B2 (ja) 2020-03-13
IL251071A0 (en) 2017-04-30
EA201790649A1 (ru) 2017-09-29
US10350206B2 (en) 2019-07-16
BR112017005444A2 (pt) 2018-04-24
KR20170049604A (ko) 2017-05-10
PE20170697A1 (es) 2017-06-24
US20170273980A1 (en) 2017-09-28
CN107001331A (zh) 2017-08-01
MX2017003664A (es) 2017-07-13
CL2017000654A1 (es) 2017-12-11
TW201615636A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
UY35500A (es) Indazoles sustituidos con heteroarilo
CR20150462A (es) Inhibidores de erk y sus usos
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20150524A (es) Compuestos de heteroarilo y sus usos
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1